Creo Medical making its mark in endoscopy

Creo Medical Group PLC is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.

Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue.

Creo Medical Group PLC (AIM:CREO) has reported a positive start to 2025 following strong first-quarter sales of its Speedboat UltraSlim and newly launched Speedboat Notch devices, as the medical technology group targets up to 60% growth in its core revenue this year.

The AIM-listed med-tech specialist said its performance in the opening months of the year had been bolstered by increasing demand from clinicians, with additional momentum expected from the commercial release of SpydrBlade Flex, a next-generation surgical instrument launched after receiving CE marking.

Management expects revenue growth to be further supported by a full-year benefit from cost savings introduced in the second half of 2024. The group is targeting an increase of 40% to 60% in sales from its core technology platform in 2025.

Creo’s core technology revenues rose by 74% year on year to £4 million in 2024, driven by the growing adoption of its minimally invasive Speedboat UltraSlim surgical tool. Over 3,000 resection procedures were performed globally using the device in its first year on the market.

Creo Medical Group PLC (AIM:CREO) has officially launched its latest surgical device, SpydrBlade Flex, in the UK and Europe, with St Mark’s Hospital in London becoming the first customer.

Designed for precision in minimally invasive procedures, the product will help doctors treat conditions like colorectal cancer without major surgery.

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford talked with Proactive about the company’s 2024 performance and its strategy for 2025. He highlighted strong growth in Creo’s core technology platform, particularly in the U.S. market, as well as the successful launch of the Speedboat Ultra Slim device in late 2023.

Gulliford also discussed the introduction of the SpydrBlade product, which is set for a full market release in 2025 alongside several other new product launches. He emphasized that Creo Medical is shifting from a development-stage company to a commercially profitable business, supported by both revenue growth and cost management.

Deutsche Bank has reiterated its 'buy' rating on Creo Medical Group PLC (AIM:CREO) with a price target of 40p following the company’s full-year results on Monday.

The target implies a near fourfold increase from the current share price of just over 10p.

Creo, which develops surgical endoscopy and advanced energy devices, reported sales of £30.7 million for 2024.

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford joins Proactive's Stephen Gunnion with the news that the company has been recognised with the King's Award for Enterprise in Innovation, an accolade honouring innovative UK companies for their impact in their respective sectors.

The award highlights Creo's influence on patient outcomes through their advanced medical technologies. Gulliford emphasised the rare honour, noting that among over five million companies in the UK, only 59 received this award this year.

The company leverages a unique combination of bipolar radiofrequency energy with microwave energy, focusing on miniaturising surgical procedures. This innovation has led to significant advancements in treatment effectiveness and cost-efficiency, particularly noted in a recent NHS case study that showcased substantial economic benefits, including a reduction in theatre costs and patient hospital stays.

The Creo Capital Markets Day provided a good overview of the strategic course of the business since the fundraising of £33.7mln (before expenses) in March 2023.